SOURCE: Aldagen


September 08, 2009 09:00 ET

Aldagen Announces Participation in Rodman & Renshaw 11th Annual Healthcare Conference

DURHAM, NC--(Marketwire - September 8, 2009) - Aldagen, Inc. today announced that Edward L. Field, President & Chief Operating Officer of Aldagen, will be presenting at the Rodman & Renshaw 11th Annual Healthcare Conference. During the presentation, Mr. Field will provide an overview of the company including recent clinical and strategic developments.

The following are specific details regarding Aldagen's presentation at the conference:

Rodman & Renshaw 11th Annual Healthcare Conference

Date: September 10, 2009

Time: 5:45 PM

Location: New York Palace Hotel, New York, NY

Room: Garrison Salon, 5th floor

About Aldagen, Inc.

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company has four product candidates in clinical trials. Aldagen's most advanced product candidate, ALD-101, is currently in a pivotal Phase 3 clinical trial to evaluate its efficacy in improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company also has three other products that are currently in, or have recently completed Phase 1 or Phase 1/2 clinical trials: ALD 151 to improve umbilical cord blood transplants used in the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. Aldagen's product candidates consist of specific populations of adult stem cells that the company isolates using its proprietary technology.

Contact Information

  • For more information, contact:

    Ed Field
    President and COO
    Email Contact

    Michelle Linn
    Linnden Communications
    Email Contact